DOI: 10.4244/EIJV11SWA12

The Arto transcatheter mitral valve repair system

Andrejs Erglis1, MD, PhD; Martyn Thomas2, MD; Marie-Claude Morice3, MD; Inga Narbute1, MD; Milana Zabunova1, MD; Thomas Hovasse2, MD; Mathieu Poupineau4, MD; Ainars Rudzitis1, MD; Ginta Kamzola1, MD; Ligita Zvaigzne1, MD; Samantha Greene5, BA; Jason H. Rogers6*, MD

Device description

Name and manufacturer: Arto™ System; MVRx, Inc., Belmont, CA, USA.

Approval status: Clinical evaluation.

Platform: Left atrial-based mitral valve repair.

Specific design: Anterior-posterior (A-P) annulus shortening of native mitral valve.

Delivery approach: Endovascular venous delivery.

Device size: 12 Fr delivery system.

Procedural details

The procedures were carried out under general anaesthesia with transoesophageal echocardiographic (TEE) guidance. The procedure has been described in detail previously1,2 and is shown in Figure 1.

Figure 1. The Arto System implantation procedure. A) Great cardiac vein (GCV) and left atrial (LA) MagneCaths in position and magnetically linked behind the P2 segment of the posterior mitral leaflet. B) Close-up of magnetically linked LA and GCV MagneCaths. Each magnetic catheter has a specific shape and lumen to direct and receive the crossing wire. C) The crossing wire (arrow) is pushed from the GCV into the LA MagneCath. The MagneCaths are aligned to direct the wire safely from the GCV to the LA through the atrial wall. D) After using an exchange catheter, the loop guidewire in place across left atrium. This guidewire directs the placement of the GCV anchor (T-bar) and septal anchor. E) The MVRx System in place before tensioning. T-bar, single arrow; septal anchor, double arrow. F) Tensioning of the bridge results in precise shortening of the mitral annulus anteroposterior diameter (arrows) and elimination of FMR; once the final position is attained, the suture is cut and secured with a suture lock.

Clinical data

Eleven consecutive patients had successful implantation of the Arto System in the MitrAl ValvE RepaIr Clinical Trial (MAVERIC Trial, clinicaltrials.gov identifier NCT02302872). The demographics and outcomes have been published previously3. All patients were deemed to be high surgical risk by the Heart Team, and were symptomatic with 81.8% being NYHA Class III/IV at baseline. There were no procedural safety events in any patient. There were two clinical events within the 30-day follow-up period: (1) one patient underwent uncomplicated surgical drainage of the effusion without recurrence, and (2) one patient had asymptomatic dislocation of the coronary sinus T-bar and underwent successful elective surgical MV replacement. No other clinical events have occurred at subsequent follow-ups.

At six months, MR grade, LV volumes, mitral annular dimensions, and functional status all improved, and were very stable when compared to 30-day values. Pre-procedure FMR was 90% grade 3-4+, and at six months was 80% grade 1-2+. EROA by PISA at baseline was 30.3±11.1, decreasing at six months to 13.7±8.6 mm2, and regurgitant volumes decreased from 45.4±15.0 to 19.9±11.6 ml. LVESVi decreased from 77.5±24.3 to 68.2±28.2 mL/m2 and LVEDVi from 118.7±28.6 to 104.9±30.2 ml/m2 at six months. Mitral annular anteroposterior diameter decreased from 45.0±3.3 to 38.9±2.7 mm. Functional status was 81.8% NYHA Class III/IV and 18.2% Class I/II at baseline, improving at six months to 50.0% Class III and 50.0% Class I/II.

Ongoing studies

Enrolment of up to 20 additional patients at three sites (Riga, Latvia; Massy, France and London, United Kingdom) is expected to begin shortly in Phase II of the MAVERIC trial.

Unique features

Unique features of the Arto System include the relatively short procedure time, as well as the absence of haemodynamic instability or ventricular arrhythmias. Device efficacy is seen immediately at the time of implantation, and the system can be adjusted by tensioning or relaxing the suture element prior to device lock and release. The Arto System is recapturable and retrievable during the deployment.

Potential improvements

With additional patient outcomes data, the preferred placement of the anchors for a given anatomy as well as the preferred amount of A-P shortening will be known and result in maximising benefits to the patient. System improvements include the addition of new anchor designs and streamlining of the catheter delivery system.

Conflict of interest statement

J. Rogers, M. Thomas, and S. Greene are consultants to MVRx. A. Erglis has an indirect equity interest in MVRx. The other authors have no conflicts of interest to declare.

Volume 11 Supplement W
Sep 17, 2015
Volume 11 Supplement W
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV16I13A190 Jan 20, 2021
Moving (re-shaping) the mitral annulus
Nickenig G and Becher M
free

MITRAL VALVE INTERVENTIONS

10.4244/EIJV12SYA23 Sep 18, 2016
Emerging technologies for direct and indirect percutaneous mitral annuloplasty
Feldman T et al
free

10.4244/EIJV11SWA14 Sep 17, 2015
Transcatheter direct mitral valve annuloplasty: a brief review
Feldman T and Guerrero M
free

10.4244/EIJV11SWA22 Sep 17, 2015
The CardiAQ transcatheter mitral valve implantation system
Søndergaard L et al
free

10.4244/EIJV11SWA10 Sep 17, 2015
Transcatheter mitral valve repair: a brief review
Barbanti M et al
free

10.4244/EIJV11SWA17 Sep 17, 2015
The Mitralign transcatheter direct mitral valve annuloplasty system
Nickenig G and Hammerstingl C
free

MITRAL VALVE INTERVENTIONS

10.4244/EIJV12SYA17 Sep 18, 2016
The Mitralign: strategies for optimal patient selection and optimised results
Schueler R and Nickenig G
free

10.4244/EIJV7I1A27 May 17, 2011
Transcatheter indirect mitral annuloplasty with the PTMA system: a technical report
Van Mieghem NM et al
free
Trending articles
152.9

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
39.1

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
38.95

State-of-the-Art

10.4244/EIJ-D-23-00912 Oct 7, 2024
Optical coherence tomography to guide percutaneous coronary intervention
Almajid F et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved